Ibrance (palbociclib)

News alerts, weekly reports and conference planners

Company:

Amgen, Pfizer

Drug class:

CDK4 inhibitor, CDK6 inhibitor

Related drugs:

‹

›

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1	palbociclib + inavolisib Sensitive: A1 - Approval palbociclib + inavolisib Sensitive : A1
No biomarker	Liposarcoma	No biomarker	Liposarcoma	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: A2 - Guideline palbociclib Resistant : A2	palbociclib Resistant: A2 - Guideline palbociclib Resistant : A2
CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER mutation	Breast Cancer	ER mutation	Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
PLK1 overexpression	Hormone Receptor Positive Breast Cancer	PLK1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	Aromatase inhibitor + palbociclib Resistant: B - Late Trials Aromatase inhibitor + palbociclib Resistant : B	Aromatase inhibitor + palbociclib Resistant: B - Late Trials Aromatase inhibitor + palbociclib Resistant : B
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ESR1 mutation	Estrogen Receptor Positive Breast Cancer	ESR1 mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ESR1 mutation	HER2 Negative Breast Cancer	ESR1 mutation	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
RB1 overexpression	Breast Cancer	RB1 overexpression	Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
CCNE1 overexpression	Breast Cancer	CCNE1 overexpression	Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
HR positive + PLK1 overexpression	HER2 Negative Breast Cancer	HR positive + PLK1 overexpression	HER2 Negative Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
HR positive + CCNE1 overexpression	HER2 Negative Breast Cancer	HR positive + CCNE1 overexpression	HER2 Negative Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	palbociclib Sensitive: C1 - Off-label palbociclib Sensitive : C1	palbociclib Sensitive: C1 - Off-label palbociclib Sensitive : C1
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
CDK4 amplification	Liposarcoma	CDK4 amplification	Liposarcoma	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	palbociclib + binimetinib Sensitive: C2 – Inclusion Criteria palbociclib + binimetinib Sensitive : C2	palbociclib + binimetinib Sensitive: C2 – Inclusion Criteria palbociclib + binimetinib Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	trametinib + palbociclib Sensitive: C2 – Inclusion Criteria trametinib + palbociclib Sensitive : C2	trametinib + palbociclib Sensitive: C2 – Inclusion Criteria trametinib + palbociclib Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	palbociclib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria palbociclib + ado-trastuzumab emtansine Sensitive : C2	palbociclib + ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria palbociclib + ado-trastuzumab emtansine Sensitive : C2
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	cetuximab + palbociclib Sensitive: C2 – Inclusion Criteria cetuximab + palbociclib Sensitive : C2	cetuximab + palbociclib Sensitive: C2 – Inclusion Criteria cetuximab + palbociclib Sensitive : C2
CDK4 overexpression	Osteosarcoma	CDK4 overexpression	Osteosarcoma	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
CDK4 overexpression	Soft Tissue Sarcoma	CDK4 overexpression	Soft Tissue Sarcoma	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
PGR expression	Breast Cancer	PGR expression	Breast Cancer	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib + ribociclib Sensitive: C2 – Inclusion Criteria palbociclib + ribociclib Sensitive : C2	palbociclib + ribociclib Sensitive: C2 – Inclusion Criteria palbociclib + ribociclib Sensitive : C2

Ibrance (palbociclib)

Associations
(222)

Associations
(222)

Ibrance (palbociclib)

Associations(222)

Associations(222)

Associations
(222)

Associations
(222)